Titan International, Inc. (NYSE:TWI) announced a definitive agreement on September 21 to sell its Italtractor ITM undercarriage business to USCO S.p.A. The initial purchase price is approximately $207 million, while the stated total cash value reaches up to approximately $285 million. Understanding that difference is central to ******* sing the financial flexibility the disposal could create.
Titan International, Inc. (NYSE:TWI) expects approximately $23 million from closing adjustments and $11 million in dividends before closing. A further $6 million depends on ITM meeting specified 2026 performance criteria. The headline also includes $38 million in dividends received in earlier years.
Subtracting those historical dividends leaves approximately $247 million in potential future gross receipts, including the earnout, or $241 million without it. These calculations use the announced estimates and span different payment dates. Final adjustments, taxes, and transaction costs will determine how much cash becomes available for deployment.
The disclosed dollar amounts were translated at €1.00 to $1.148, the September 18, 2026 exchange rate. Currency movements could increase or reduce the eventual dollar receipts.
Titan International, Inc. (NYSE:TWI) intends to use part of the proceeds to reduce debt and pursue growth investments, including acquisitions and partnerships. The disposal would also concentrate resources on wheel and tire operations.

#september #announced

Vista Gold Corp. (NYSEAMERICAN:VGZ) announced on September 21 that it had agreed to be acquired by Artemis Gold Inc. (TSXV:ARTG). Under the agreement signed September 20, shareholders would receive 0.0966 buyer common shares for each existing common share and own approximately 5% of the combined company. That ownership calculation excludes the buyer's existing 4.95% stake in Vista Gold Corp. (NYSEAMERICAN:VGZ), which it intends to cancel at completion.
For shareholders, the trade-off is a smaller interest in a larger mining business with an operating ***** et and development expertise. The central question is whether that combination can supply the capital and execution needed to bring Australia's Mt Todd gold project into production.
Artemis Gold Inc. (TSXV:ARTG) operates the Blackwater mine in British Columbia and expects its future cash generation to support Mt Todd. That offers Vista Gold a potential funding source alongside a team experienced in building and operating mines.
The financial starting point explains the appeal. Vista Gold Corp. (NYSEAMERICAN:VGZ) ended June 2026 with $49.5 million in cash and no debt. Management described that cash as sufficient for interim development objectives. Joining an operating producer could broaden the resources available for the much larger task of construction.
The acquisition requires no cash consideration or new acquisition debt. Preserving the buyer's financial capacity could leave more room for investment, although the share exchange itself does not raise construction funding.

#cash

A Wall Street Journal report on September 16 revealed that ExxonMobil Holdings Corporation (NYSE:XOM) is nearing a preliminary agreement with Venezuela's state-owned PDVSA, potentially marking its return to the country almost two decades after its ***** ets were nationalized. According to Reuters, Exxon has shown interest in the large Petromonagas heavy oil project in the Orinoco Belt, as well as in areas in the neighboring Carabobo block.
While the talks are still in their preliminary phase and could still fall apart or be delayed, they mark a major turnaround from Exxon's previous stance on Venezuela. The company's CEO, Darren Woods, stated in January that the country was "uninvestable" without durable investment protections, legal reforms, and changes to its hydrocarbon laws.
The development comes amid a broader push by the Trump administration to open Venezuela's oil industry to American companies and revive the country's dilapidated oil infrastructure. The South American nation is sitting on the largest proven crude oil reserves in the world, accounting for roughly 17% of the global total.
Venezuela could provide Exxon with access to an enormous resource base at a time when the company is actively seeking low-cost and long-duration ***** ets. The fields under consideration are estimated to contain more than 50 billion barrels of oil buried underground.
Exxon already holds an advantage through its previous experience in the country. Petromonagas, formerly called Cerro Negro, was once the energy firm's flagship project in Venezuela, giving it familiarity with the country's vast heavy and extra-heavy crude resources. Petromonagas also remains one of the few Venezuelan projects with an operational upgrader capable of turning the Orinoco's extra-heavy crude into lighter exportable grades.

#heavy #project

California Resources Corporation (NYSE:CRC) announced on September 17 that it had agreed to sell its Uinta Basin **** ets, located mostly in Utah and Colorado, to an undisclosed buyer for $90 million in cash. The company had come to own the Uinta **** ets, which span about 100,000 net acres, after it acquired Berry Corp last year. However, CRC considered them non-core to its operations. The net proceeds from the sale will be used for shareholder returns and other corporate purposes.
Francisco Leon, President and CEO of California Resources Corporation, commented:
"Today's transaction strengthens our business. The monetization of our Uinta Basin **** ets sharpens our focus on California and captures additional value from the Berry merger. This transaction enhances our capital allocation flexibility, allowing us to invest in higher-return opportunities within the Golden State and supports our shareholder return strategy. The sale also helps offset the purchase price of our recent midstream transaction."
The transaction is expected to close by year-end, subject to the receipt of certain third-party consents and other customary conditions.
The sale will allow CRC to redeploy the $90 million toward **** ets that are central to its operating strategy while avoiding additional capital commitments to Uinta. The company already stated in its Q2 earnings call that Uinta has higher capital intensity, higher break-evens, lower crude quality, higher transportation and operating costs, and steeper declines. Therefore, the sale removes a portfolio distraction at a time when CRC is concentrating investment in California infrastructure and production.

#uinta #assets #transaction #capital

Targa Resources Corp. (NYSE:TRGP) has significantly outperformed the wider market this year, posting gains of over 56% since the beginning of 2026. A major catalyst behind this growth was the 20-year fee-based agreement that the company signed with ExxonMobil last month.
While there are concerns that the stock's rally may have topped out, the **** ysts over at TD Cowen see further growth ahead. On September 18, the firm upgraded TRGP from 'Hold' to Buy', while also boosting its price target from $275 to $350. The revised target implies an upside of almost 20% from the current levels and even exceeds the stock's record high of just under $308 achieved last month.
TD Cowen cited Targa's expected Permian Basin wet gas growth and peer-leading EBITDA growth for the upgrade. The **** yst expects the company's free cash flow yield to rise from 6% in 2026 to more than 10% in 2028, compared with an estimated 8.5% FCF yield for peers in 2030. The improvement is expected to be driven by EBITDA growth from new processing plants and the completion of a major capital project in the Speedway NGL pipeline.
According to TD Cowen, a key driver for Targa's growth is the rising wet gas production in the Permian, which means that the **** yst's thesis is tied to physical volume growth rather than simply a higher-commodity price **** umption.
Targa's recently announced deal with ExxonMobil provides greater visibility into future volumes and infrastructure demand. The company has also planned three new natural gas processing plants in the Permian Delaware as part of the deal, with an aggregate capacity of roughly 825 MMcf/day. Targa expects this agreement to add significantly to its "strong growth rate well into the next decade and bolster its outlook for durable and growing adjusted free cash flow over the long term".

#exxonmobil #ebitda

Shell plc (NYSE:SHEL) is a global group of energy and petrochemical companies with a presence in over 70 countries. The stock has delivered gains of over 23% since the beginning of 2026 and even hit its all-time high earlier in March, driven primarily by soaring oil prices and solid earnings amid supply disruptions in the Middle East.
Following a slight pullback over the last few months, Shell has started to regain momentum, and Morgan Stanley expects the rally to continue. On September 3, the investment bank upgraded SHEL from 'Equal Weight' to 'Overweight', while also raising its price target from $81.60 to $101.30. The target boost implies an upside of 9% from the current levels and even exceeds Shell's previous record high of almost $95 per share achieved earlier this year.
Morgan Stanley noted that the concerns surrounding Shell's long-term resource longevity have now eased, with the company now positioned to sustain production growth through 2030 and stabilize output thereafter. The ******* yst firm believes that while the stock has been weighed down due to its dividend policy, there is now "potential for a significant acceleration. As a result, Morgan Stanley promoted SHEL to top-pick status.
Shell completed the acquisition of ARC Resources earlier this month, addressing the resource-depletion concerns that have weighed down its valuation. The $16.4 billion deal has significantly expanded the energy giant's gas reserves and will boost its production by 370,000 boed. Additionally, the strategic move expands Shell's exposure to the North American gas market and bolsters its position in a region that is emerging as a key player in the global LNG supply.
Shell's recent upstream investments provide further support to Morgan Stanley's bullish thesis. The company announced earlier this month that it had agreed to acquire a 30% interest in BP's Conifer exploration prospect in the US Gulf, and a 50% stake in the Tupinamba exploration block in Brazil's Santos Basin. Additionally, it also recently signed a preliminary agreement for the acquisition of production rights over Ghana's South Deepwater Tano Cape Three Points ‌oil and gas block.

#shel #production #energy #Stock

On August 6, Targa Resources Corp. (NYSE:TRGP) reported a record second quarter. Adjusted EBITDA reached $1.60 billion, a 38% jump from the same period a year earlier, and management now expects full-year results near the top of its guidance range. Targa moves and processes natural gas and natural gas liquids out of the Permian Basin, and these numbers suggest that system is running fuller than ever.
The strength came from volume, not just price. Adjusted EBITDA also climbed 14% from the first quarter, helped by Permian gas volumes that added over 450 million cubic feet of daily throughput. Some producers held back output because Waha gas prices went negative, and Targa still set a volume record. Volumes for NGL pipelines, fractionation, and LPG exports also hit records, helped by Train 11, a new fractionator in Mont Belvieu, Texas, that started up early in the quarter.
Construction is also landing on time. East Driver, a new processing plant serving the Midland side of the Permian, started up late in the quarter and ahead of schedule, and the other gathering and logistics projects are tracking their plans. Shareholders get a cut too. On July 16, Targa declared a $1.25 per share quarterly dividend, 25% above the payout for the second quarter of 2025, payable August 14 to holders of record on July 31. It also spent $80 million buying back shares during the quarter.
Growth at this pace costs real money. Targa plans about $4.5 billion in net growth spending this year, and its consolidated debt stood at $19,578 million on June 30. About $3.2 billion of liquidity gives it a cushion. In July, it also extended its receivables securitization facility to July 30, 2027 and raised the size to as much as $800 million. More borrowing capacity helps, but it is still borrowing.
Not every dollar of the profit surge is as steady as a pipeline volume. Management tied the higher outlook partly to strong marketing margin and optimization work in the first two quarters, and the quarter's jump in marketing margin came from greater optimization opportunities. That kind of income can be lumpy. Meanwhile, lower natural gas prices trimmed margins in the gathering business, and the Waha curtailments showed that producers can pull back when local prices turn ugly.

#record

Claiming Social Security at 62 gives you three extra years of payments, but each monthly check is permanently smaller than it would be if you had waited until 65. Delaying benefits means giving up that early income in exchange for a larger monthly payment later. The break-even point shows when those larger checks catch up to the benefits collected by claiming early. Comparing that crossover age with your income needs, life expectancy and other retirement resources can help put the tradeoff in context.
A financial advisor can review a range of retirement strategies with you, including your optimum retirement age.
Social Security benefits can generally begin at age 62. However, starting before full retirement age (FRA) permanently reduces the monthly amount you receive. FRA depends on your birth year and ranges from 66 to 67 for workers approaching retirement today. For anyone born in 1960 or later, FRA is 67.
The Social Security Administration calculates early-claiming reductions based on how many months before FRA you begin collecting benefits. For the first 36 months before FRA, the benefit is generally reduced by 5/9 of 1% for each month. If you claim more than 36 months early, the reduction for those additional months is generally 5/12 of 1% per month.1
For a worker with an FRA of 67, claiming at 62 generally results in a 30% reduction. This means the worker receives about 70% of the benefit they would have received at FRA. Someone entitled to $2,500 per month at 67, for example, would receive approximately $1,750 per month by claiming at 62.

#Retirement

By Stine Jacobsen, Jacob Gronholt-Pedersen and Tom Little
COPENHAGEN, Sept 19 (Reuters) - Denmark and Greenland on Saturday said any agreement with the United States would not compromise Greenland's sovereignty, after President Donald Trump said the deal would give Washington "permanent control" over the Arctic ‌island's security, leaving its precise scope unclear.
The United States, Denmark and Greenland said late on Friday they had reached an agreement ‌for the US to develop a significant military presence on Greenland, while prohibiting US adversaries from building their own bases on the island.
Key details of the agreement have not been made public, including the scale of US military presence in the self-governing Danish territory and whether any formal power over foreign policy and resources would be ceded to Washington.
Denmark and Greenland expressed hope that a deal, which is expected to be signed during the UN General ******* embly next week, would end months of uncertainty triggered by Trump's threats to seize control of Greenland.

#greenland #control

UEC holds $488M cash with zero debt and actual uranium production; NXE's 257M lb Arrow deposit draws 16 unanimous ***** yst buy ratings averaging $19.
Utilities are structurally short contracted uranium pounds, and the last US mine permitting took 14 years, which helps explain why in-ground resources command extreme revenue multiples.
Denison's Phoenix is Canada's first uranium mine approved for construction in 20 years, with 8M+ lbs already contracted and first production targeted for mid-2028.
Just released. Our ***** ysts combed the entire stock market and named the ten best stocks to buy right now, and NexGen Energy didn't make the cut. Enter your email to see the names that beat NXE. The report is free. Enter your email and see if any of your stocks made the cut.
Uranium mining is the narrow end of the funnel feeding the AI-driven reactor buildout. On April 23, the U.S. Department of Energy launched the Nuclear Dominance 3x33 campaign to secure the domestic nuclear fuel supply chain and support future reactor deployment, and utilities are staring at a widening long-term supply gap while a Russian enriched-uranium ban takes hold.

#enter #contracted

On September 15, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) completed its acquisition of privately held Actio Biosciences for $820 million upfront, adding a clinical-stage epilepsy drug called ABS-1230 to its rare disease pipeline. The deal lands weeks after Jazz posted its highest quarterly revenue ever on August 3, and raised its full-year guidance, so a fresh acquisition now sits on top of a business that was already accelerating. The question for investors is whether that combination adds up to durable growth or just a bigger bill.
ABS-1230 targets KCNT1-related epilepsy, a rare and hard-to-treat form of the disease. In an early clinical proof-of-concept trial, children who received the drug experienced meaningful seizure reductions, and preclinical testing showed it inhibited KCNT1 across every pathogenic mutation researchers evaluated, hinting it could work across the whole patient population rather than a narrow subset. The FDA has already granted ABS-1230 Orphan Drug, Rare Pediatric Disease and Fast Track designations, and accepted it into the agency's Rare Disease Evidence Principles process, a set of regulatory advantages that can speed a drug toward approval.
The acquisition also arrives while Jazz's existing business is firing on multiple cylinders. Second-quarter revenue climbed 16% year over year to $1.2 billion, the company's highest quarterly total on record, and management raised full-year 2026 revenue guidance to a range of $4.6 billion to $4.75 billion. Growth was not confined to one product. Xywav sales rose 13% to $471 million on 525 net new patients, Epidiolex grew 16% to $292 million, and Zepzelca jumped 42% to $106 million. Zanidatamab, sold as Ziihera in biliary tract cancer, also received Breakthrough Therapy designation from the FDA for a form of colorectal cancer, adding another avenue for the oncology franchise Jazz has been building beyond its epilepsy and sleep businesses.
None of that came free. The $820 million upfront payment for Actio lands on top of $4.4 billion in long-term debt that Jazz already carried as of June 30, even after the company used part of its cash to repay $1.0 billion of exchangeable notes that matured this year. Cash, equivalents and investments stood at $2.2 billion at that point, meaning the Actio payment alone accounts for a meaningful share of the company's liquid resources.
Jazz's recent history also shows how acquisitions can distort the bottom line before they pay off. A $905.4 million in-process research and development charge tied to the 2025 Chimerix acquisition pushed second-quarter 2025 GAAP earnings to a loss of $11.74 per share, and a smaller $77 million IPR&D charge from the AbCellera and Werewolf deals still dented second-quarter 2026 results. ABS-1230 itself remains early, with only proof-of-concept data in hand and no late-stage trial results yet. The portfolio is not without setbacks, either. Jazz is moving to voluntarily drop the second-line indication for Zepzelca in meta

On September 7, 2026, Reuters reported that Novo Nordisk A/S (NYSE:NVO) halted two additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker's efforts to diversify beyond its blockbuster obesity and diabetes franchise.
The move follows a July disclosure that ziltivekimab failed to reduce major adverse cardiovascular events in a late-stage trial. An independent data monitoring committee found a "low likelihood" that the two additional heart-failure studies would produce a different result from that earlier failure, prompting Novo to end them ahead of schedule.
Novo Nordisk A/S (NYSE:NVO) still has one opportunity to create value from its cardiovascular program. The company will continue testing ziltivekimab in patients recovering from a heart attack, with results expected in the first half of 2027. A successful outcome could give Novo another growth opportunity outside its obesity and diabetes franchise.
Novo's core obesity and diabetes business remains the much larger driver of its financial performance. The oral Wegovy pill has already generated more than 2 million prescriptions shortly after its January 2026 launch. It gives Novo an important growth opportunity as the company competes with Eli Lilly in the oral GLP-1 market.
The company can also preserve capital by ending trials that show limited prospects for success. An independent data monitoring committee found a low likelihood that the two heart-failure studies would produce different results from the earlier failed trial. Novo can redirect the resources it would have spent on those studies toward higher-potential programs.

#obesity #diabetes

On September 9, 2026, Reuters reported that U.S. Transportation Secretary Sean Duffy sent a letter to Ford Motor Company (NYSE:F) CEO Jim Farley criticizing the automaker's business relationships with Chinese battery maker CATL and Chinese automakers Geely and BYD as raising "profound concern."
It specifically flagged Ford's licensed CATL battery technology at its Marshall, Michigan plant, its joint venture with Geely in Spain, and its decision not to move Lincoln Nautilus production out of China until 2030. Ford responded that Duffy's letter was "a wrongheaded attempt to capture headlines," noting that it owns the Marshall plant, controls its operations, and employs the workforce there, unlike companies that simply import Chinese-made batteries.
Ford Motor Company (NYSE:F) can argue that its CATL partnership still solidifies U.S. battery manufacturing rather than becoming more dependent on Chinese imports. Ford owns and operates its Marshall, Michigan battery plant. It allows the company to manufacture batteries domestically while licensing CATL technology. That structure could help Ford expand its U.S. EV production capacity and reduce the need to import finished Chinese battery packs.
Ford's improving financial performance gives the firm more flexibility to manage the political pressure. The automaker raised its full-year adjusted EBIT guidance to $10 billion-$11 billion after second-quarter results exceeded expectations, with record Bronco sales and a stronger product mix supporting the improvement. Stronger operating earnings could give Ford more resources to adjust its battery strategy if policymakers impose more restrictions on Chinese technology.
The company's existing U.S. manufacturing footprint could become a competitive advantage if Washington tightens restrictions on Chinese automotive technology. Ford has already invested in domestic battery production instead of relying entirely on imported battery packs. Model e losses have narrowed for three consecutive quarters. If policymakers force automakers to cut Chinese supply-chain reliance, Ford can use its existing U.S. factories to adapt faster than rivals that depend heavily on Chinese parts.

#ford #catl #motor

On September 8, 2026, Reuters reported that NIKE, Inc. (NYSE:NKE) shareholders rejected a proposal urging greater transparency on how the company plans to meet its 2030 emissions-reduction targets, despite support from Norway's sovereign wealth fund, Nike's 11th-largest shareholder.
Nike's board had urged a "no" vote, arguing management is "best positioned to determine the targets and related disclosures that are appropriate." Shareholders separately approved the company's executive compensation proposal, including pay for CEO Elliott Hill, in a vote that had faced some opposition.
The failed climate proposal gives NIKE, Inc. (NYSE:NKE)'s management more flexibility to focus on its operational turnaround. Shareholders rejected the request for greater disclosure on how Nike plans to meet its 2030 emissions targets. It allows CEO Elliott Hill and his team to prioritize product innovation, sales recovery, and market-share gains. Nike faces significant operational challenges. So management could benefit from directing more resources toward restoring growth and profitability.
Nike has already made measurable progress toward its environmental targets. It limits the immediate financial impact of the rejected proposal. The company reported an 11% reduction in supply-chain emissions from its 2015 baseline in fiscal 2024, while its 2030 targets call for a 65% reduction in operational emissions and a 30% reduction across its supply chain. This progress gives Nike evidence that it is chasing its climate goals even without expanding its current disclosure.
Shareholders' approval of Elliott Hill's compensation package shows support for Nike's leadership despite the difficult turnaround. Investors approved more than $36 million in total compensation for Hill for fiscal 2026, even though Norway's wealth fund and major proxy advisers opposed the package. Shareholder support gives Hill greater room to execute his strategy as Nike works to stabilize sales, rebuild its market position, and restore long-term earnings growth.

#reduction #elliott #greater

This story was originally published on Bisnow, the newsroom global commercial real estate reads first. To receive daily news and **** ysis, subscribe to Bisnow's free suite of newsletters.
The following article is a collaboration between Bisnow and business tech publication IT Brew.
It was Thanksgiving week in 2022 — a time when most employees are hard to find, let alone critical pieces of data center power infrastructure. And Kurt Bogle needed a transformer.
Bogle, then a senior regional director of critical facilities operations at NTT Global Data Centers, oversaw seven operational buildings around Chicago and Virginia and a staff of about 150 people. After a transformer failed a test, Bogle had to find a replacement and coordinate a swap with the on-site managers — all without disrupting service.
Thankfully, Bogle found a spare, but his experience illustrates the importance of systems thinkers at data centers who know how to acquire the resources necessary to maintain data centers' high uptime expectations. Given supply chain limitations and a steady build-out of data centers, such expertise is more crucial than ever — and there are signs a labor shortage is underway, threatening Big Tech's artificial intelligence ambitions and the reliable operation of mission-critical facilities.

#data #critical

Ascendis Pharma A/S (NASDAQ:ASND) announced on September 14 that it will regain exclusive rights to develop, manufacture, and commercialize TransCon products in metabolic and cardiovascular diseases following the termination of its collaboration with Novo Nordisk A/S (NYSE:NVO).
The rights include once-monthly TransCon Semaglutide, an investigational long-acting prodrug of semaglutide intended for obesity and type 2 diabetes. Neither party will have continuing financial obligations to the other. Once termination becomes effective and the rights revert, management plans to initiate multiple programs across rare and large indications.
The investment question is whether greater control over future products can justify the resources needed to develop them.
Ascendis Pharma A/S (NASDAQ:ASND) would regain flexibility over which indications to pursue, how quickly to advance candidates, and whether to seek another partner. Successful independent development could retain more of a product's commercial economics, while a new collaboration could provide another way to share costs and risk.
Monthly dosing offers a clear development objective. If clinical studies demonstrate effective treatment with acceptable tolerability, fewer injections could make long-term therapy more convenient. That potential benefit would matter most if it helps patients stay on treatment without sacrificing outcomes.

#ascendis #pharma #asnd #regain

Guardian Metal Resources PLC (NYSEAMERICAN:GMTL) reported its first Good Hope drilling results on September 14, adding exploration potential to the Pilot Mountain tungsten project in Nevada. Hole GH26-01 returned a 12.95-meter downhole interval grading 0.79% tungsten trioxide, or WO3, starting at 12.19 meters. GH26-02 intersected 13.11 meters at 0.42% WO3 from 2.13 meters.
The holes were twinned, with GH26-02 redrilling the upper portion where core had not been recovered. Good Hope and the separate Tremor discovery remain outside the resource base supporting the existing pre-feasibility study. The investment question is whether additional mineralization can improve project returns without slowing development.
Shallow mineralization offers a potential route to additional feed that could be accessible early in a future mining sequence. Good Hope sits approximately 1.1 to 1.3 kilometers from the existing resource areas, making its possible integration worth evaluating alongside the planned operation.
The June pre-feasibility study models an eight-year open-pit operation based on Desert Scheelite and Garnet. If further work establishes economic resources at Good Hope or Tremor, additional feed could extend that operating life or improve the sequence in which material reaches the processing plant.
For Guardian Metal Resources PLC (NYSEAMERICAN:GMTL), the potential benefit is better use of infrastructure already contemplated for Pilot Mountain. That would depend on recoverable metal, processing compatibility, and the additional capital required to bring the new zones into production.

#hope #resources #guardian

Alcoa Corporation (NYSE:AA) priced $2.6 billion of acquisition financing on September 9, 2026, through two wholly owned subsidiaries. Alumina Pty Ltd will issue $1.5 billion of 6.625% notes due 2034, while Alcoa Nederland Holding B.V. will issue $1.1 billion of 6.875% notes due 2036. Alcoa Corporation (NYSE:AA) and certain subsidiaries will guarantee the notes on a senior unsecured basis.
The tranches imply annual coupons of $99.375 million and $75.625 million, respectively, totaling exactly $175 million. Settlement is expected on September 23. Net proceeds and cash on hand would fund the approximately $3.1 billion cash portion of the South32 Limited (ASX:S32) ****** et acquisition, plus related fees and expenses.
For Alcoa Corporation (NYSE:AA), successful settlement would secure longer-dated funding and allow termination of the remaining 364-day bridge commitments. Maturities in 2034 and 2036 give management time to integrate the ****** ets before principal comes due.
The operating opportunity lies in linking additional bauxite resources, alumina refining and aluminum production. Better coordination could strengthen feedstock security and improve purchasing, logistics and plant economics. Acquired earnings and operating improvements could produce recurring cash to service the debt while funding reinvestment.
Fixed coupons also make the interest burden predictable. Strong ****** et performance could support debt reduction and give shareholders a growing share of incremental cash generation.

#notes #september

Interested in The Goldman Sachs Group, Inc.? Here are five stocks we like better.
Goldman Sachs expects its revenue base to reach roughly $70 billion this year, up from the mid-$30 billion range when its strategic plan began in 2018–19, supported by greater diversification and operating leverage.
Asset & Wealth Management is exceeding its targeted high-single-digit growth rate, overseeing about $4 trillion in ******* ets and targeting 30% margins and high-teen returns. Acquisitions and partnerships are expanding its alternatives, ETF, retirement and real estate capabilities.
Goldman expects alternatives fundraising above $125 billion this year and sees major financing opportunities from AI infrastructure investment, while near-term results may face higher expenses, softer FICC activity and a muted investments line.
Digging for Value: Alpha Metallurgical Resources Insider Buys Big

#year #here

Teck Resources Ltd (NYSE:TECK) stock's pullback from its Sept. 8 record high of $72.56 has found support at the 60-, 80-, and 100-day moving averages. The 100-day trendline in particular is a historically bullish signal that presents an intriguing 'buy the dip' angle.
Per Schaeffer's Senior Quantitative ******* yst Rocky White, TECK has traded within 0.75 times the 100-day moving average's 20-day average true range (ATR) after spending at least 80% of the previous two weeks and 80% of the prior 42 trading sessions above the trendline. This setup has occurred eight other times over the last decade, after which the stock was higher one month later 75% of the time, averaging a large 13.8% gain.
Short interest accounts for a healthy 7.5% of the stock's available float, leaving ample sideline buying power should some of these bearish bets begin to unwind. TECK's 14-day Relative Strength Index (RSI) of 28.4 also sits in "oversold" territory, which often precedes a short-term bounce.
Plus, TECK's Schaeffer's Volatility Scorecard (SVS) sits at 81 out of 100, suggesting the shares have tended to outperform options traders' volatility expectations during the past year.

#resources

This story was originally published on CFO Dive. To receive daily news and insights, subscribe to our free daily CFO Dive newsletter.
Business executives consider artificial intelligence a leading tool for decision-making, with 61% citing large language models such as ChatGPT, Claude, Gemini and Copilot among the sources that most influence their strategic decisions, AI enterprise planning platform Board said in a report released Wednesday.
The finding was most ***** ounced among CFOs, with 69% citing LLMs among the resources that inform their decisions, compared with 58% of chief operating officers and 56% of chief information officers.
"CFOs, by nature, are typically a little bit more conservative and skeptical, so I think what this shows is that the AI wave is so strong that it can't be ignored," Board CFO Gordon Pothier said in an interview.
The findings come just a few years after ChatGPT burst onto the market, highlighting how quickly advanced AI tools have reshaped the way businesses operate and make decisions.

#decisions #daily #officers #business

Oracle Corporation (NYSE:ORCL) is increasing the expected cost of its fiscal 2026 restructuring plan by about $700 million to roughly $2.8 billion as it simultaneously ramps up spending to capture demand for AI cloud services. The additional costs include severance, contract terminations and other exit expenses, with some restructuring directly linked to adopting AI across parts of the organization.
Oracle had already recorded $1.8 billion of restructuring expenses in fiscal 2026, compared with $299 million in fiscal 2025, showing how materially the company is accelerating its operational transformation. The restructuring comes alongside an unusually large AI investment cycle. Oracle booked more than $30 billion of new AI cloud contracts in its latest quarter, lifting its remaining performance obligations/revenue backlog to $664 billion, while roughly half of that backlog is expected to convert into revenue over the next 36 months.
The strongest bull argument is that the additional restructuring expense is part of a broader shift toward a higher-growth cloud and AI business rather than simply a deterioration in cost control. Oracle Corporation (NYSE:ORCL)'s restructuring program is explicitly aimed at improving efficiency while reallocating resources toward cloud-based offerings and second-generation cloud infrastructure. If the $2.8 billion restructuring program reduces lower-growth costs and enables Oracle to redirect personnel and capital toward AI infrastructure, the near-term earnings pressure could support stronger operating leverage later as cloud revenue scales.
More importantly, the restructuring is occurring against evidence that AI demand is already translating into contracted revenue. Oracle added more than $30 billion of AI cloud contracts in one quarter, pushing its backlog to $664 billion, above the $639.89 billion ******* yst estimate. Management said most of the newly contracted revenue would not require substantial incremental capital because customers are using prepayments or supplying their own hardware. That is particularly important because Oracle's biggest weakness has been the mismatch between rapid infrastructure investment and current cash generation. If customer-funded capacity continues to reduce Oracle's upfront capital burden, the company could convert its huge backlog into revenue without proportionally increasing its cash burn.
The early financial evidence also supports the possibility that the AI strategy is beginning to improve Oracle's growth profile. Revenue in the recent quarter rose 30% year over year to $19.3 billion, adjusted EPS reached $1.92 versus the $1.74 ******* yst consensus, and Oracle Corporation (NYSE:ORCL) raised its fiscal 2027 adjusted EPS forecast from $8.05 to $8.10. Meanwhile, first-quarter free cash flow of negative $5.4 billion was substantially better than both the expected negative $9.56 billion and the previous-quarter negative $11.48 billion. If this trajectory continues, the $700

Apollo Global Management, Inc. (NYSE:APO) is reportedly in talks to acquire Johnson & Johnson (NYSE:JNJ) DePuy Synthes orthopedics business in a transaction that could value the unit at close to $20 billion, according to Bloomberg, as reported by Reuters. J&J generated $9.3 billion of revenue from the orthopedics business in 2025, making the potential transaction material for both companies. The discussions could reach an agreement within weeks, although J&J is also considering a public-market spin-off. This is consistent with J&J's October 2025 decision to separate DePuy Synthes within an expected 18-to-24-month timeframe and shift its MedTech portfolio toward higher-growth, higher-margin businesses.
For Apollo Global Management, Inc. (NYSE:APO), the attraction is the opportunity to acquire a large, established medical-device franchise with substantial recurring demand from joint-replacement and surgical procedures. A roughly $20 billion valuation against $9.3 billion of 2025 revenue implies a price-to-sales multiple of about 2.2x, giving Apollo room to pursue operational improvements, portfolio rationalization, and margin expansion if the business is acquired at an attractive valuation.
DePuy Synthes also has meaningful scale and leading positions across major orthopedics categories, while J&J has recently invested in technologies that could strengthen the franchise, including an agreement covering Gemtrack tracking technology for robotic and navigation-assisted joint procedures and the acquisition of Expanding Innovations for expandable spine implants. Apollo is also entering the potential deal from a position of considerable financial scale: it had approximately $1.05 trillion of ***** ets under management as of June 30, 2026, with $198 billion in equity strategies and $849 billion in credit strategies. Its second-quarter results included $111 billion of gross capital deployment, demonstrating the capacity to execute large transactions.
For Johnson & Johnson (NYSE:JNJ), a sale could accelerate the portfolio transformation that management has already identified as a strategic priority while potentially delivering a sizeable upfront cash inflow. J&J explicitly said its planned orthopedics separation should increase the company's top-line growth and operating margins by allowing it to concentrate on Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision.
The company has also been restructuring orthopedics, with $307 million of restructuring expense in 2025, following $167 million in 2024 and $319 million in 2023, primarily tied to market and product exits. A sale could therefore remove a business that has required restructuring resources while allowing J&J to redeploy capital toward areas it views as higher growth and higher margin.

#billion #depuy

Colgate-Palmolive Company (NYSE:CL) is reportedly exploring the sale of several mass-market personal care brands, including Softsoap, Irish Spring and Speed Stick, in a portfolio reshaping effort that could generate more than $1 billion. The company is working with Goldman Sachs on the potential divestiture. Personal care accounted for roughly 17% of Colgate-Palmolive's 2025 net sales, or about $3.5 billion, while oral care remains the company's largest business.
The move comes as Colgate faces pressure in its North American business. Although the company recently reported a 4.9% increase in net sales, organic sales in North America declined 3%, highlighting competitive pressure in a mature market. The strategy is also consistent with a broader consumer-goods shift toward simplifying portfolios and concentrating capital on higher-growth categories. Unilever, Nestlé, and other major consumer companies have similarly been selling slower-growing or non-core businesses.
The biggest positive is that Colgate-Palmolive Company (NYSE:CL) could become a more focused and potentially higher-quality business. Selling brands that no longer fit its highest-priority growth areas would allow management to concentrate capital, marketing spending, and management attention on oral care, pet nutrition, and other businesses where Colgate has stronger competitive advantages. The company's decision would therefore be less about abandoning personal care altogether and more about improving the quality of the remaining portfolio.
A sale could also unlock meaningful shareholder value. If the divestitures generate more than $1 billion, Colgate would have additional capital that could be used for debt reduction, share repurchases, acquisitions, or investment behind its strongest brands. In a mature consumer-staples company, disciplined capital allocation can have an outsized impact on earnings growth and shareholder returns. There is also evidence that portfolio simplification is becoming increasingly attractive across the consumer-goods industry. The Wall Street Journal has highlighted how companies such as Unilever and Nestlé are shedding businesses that add complexity without providing sufficient growth. The underlying argument is that the benefits of owning a very broad portfolio have diminished as consumer preferences become more fragmented and smaller brands become better at responding to trends.
Most importantly, the divestiture could improve Colgate-Palmolive Company (NYSE:CL)'s strategic focus at a time when North American competition is challenging. Rather than allocating resources to defend slower-growing personal-care brands, management could direct investment toward categories and geographies with better long-term growth prospects. That could ultimately support margins and organic growth even if the immediate revenue base becomes smaller.

#personal #NYSE #Portfolio

Targa Resources Corp. (TRGP), headquartered in Houston, Texas, owns, operates, acquires, and develops a portfolio of complementary domestic infrastructure ***** ets. Valued at $62.2 billion by market cap, the company's ***** ets connect natural gas and NGLs to domestic and international markets with growing demand for cleaner fuels and feedstocks.
Companies worth $10 billion or more are generally described as "large-cap stocks," and TRGP perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the oil & gas midstream industry. TRGP benefits from strategic positioning in key shale plays including Permian, STACK, SCOOP, and Bakken, giving it a competitive edge in midstream. Its diversified service portfolio, including the Grand Prix NGL pipeline and Mont Belvieu fractionation capacity, underpins a strong market presence and stable revenue base.
Goldman Sachs Expects Fed Chair Kevin Warsh to Raise Rates This Week — But Not Because of Oil Prices.
Middle East Supply Constraints Lift Crude Oil Prices
Crude Prices Soar as Global Oil Supplies Continue to Tighten

#market

Oracle Corporation (NYSE:ORCL) is increasing the expected cost of its fiscal 2026 restructuring plan by about $700 million to roughly $2.8 billion as it simultaneously ramps up spending to capture demand for AI cloud services. The additional costs include severance, contract terminations and other exit expenses, with some restructuring directly linked to adopting AI across parts of the organization.
Oracle had already recorded $1.8 billion of restructuring expenses in fiscal 2026, compared with $299 million in fiscal 2025, showing how materially the company is accelerating its operational transformation. The restructuring comes alongside an unusually large AI investment cycle. Oracle booked more than $30 billion of new AI cloud contracts in its latest quarter, lifting its remaining performance obligations/revenue backlog to $664 billion, while roughly half of that backlog is expected to convert into revenue over the next 36 months.
The strongest bull argument is that the additional restructuring expense is part of a broader shift toward a higher-growth cloud and AI business rather than simply a deterioration in cost control. Oracle Corporation (NYSE:ORCL)'s restructuring program is explicitly aimed at improving efficiency while reallocating resources toward cloud-based offerings and second-generation cloud infrastructure. If the $2.8 billion restructuring program reduces lower-growth costs and enables Oracle to redirect personnel and capital toward AI infrastructure, the near-term earnings pressure could support stronger operating leverage later as cloud revenue scales.
More importantly, the restructuring is occurring against evidence that AI demand is already translating into contracted revenue. Oracle added more than $30 billion of AI cloud contracts in one quarter, pushing its backlog to $664 billion, above the $639.89 billion ****** yst estimate. Management said most of the newly contracted revenue would not require substantial incremental capital because customers are using prepayments or supplying their own hardware. That is particularly important because Oracle's biggest weakness has been the mismatch between rapid infrastructure investment and current cash generation. If customer-funded capacity continues to reduce Oracle's upfront capital burden, the company could convert its huge backlog into revenue without proportionally increasing its cash burn.
The early financial evidence also supports the possibility that the AI strategy is beginning to improve Oracle's growth profile. Revenue in the recent quarter rose 30% year over year to $19.3 billion, adjusted EPS reached $1.92 versus the $1.74 ****** yst consensus, and Oracle Corporation (NYSE:ORCL) raised its fiscal 2027 adjusted EPS forecast from $8.05 to $8.10. Meanwhile, first-quarter free cash flow of negative $5.4 billion was substantially better than both the expected negative $9.56 billion and the previous-quarter negative $11.48 billion. If this trajectory continues, the $700 mi

Apollo Global Management, Inc. (NYSE:APO) is reportedly in talks to acquire Johnson & Johnson (NYSE:JNJ) DePuy Synthes orthopedics business in a transaction that could value the unit at close to $20 billion, according to Bloomberg, as reported by Reuters. J&J generated $9.3 billion of revenue from the orthopedics business in 2025, making the potential transaction material for both companies. The discussions could reach an agreement within weeks, although J&J is also considering a public-market spin-off. This is consistent with J&J's October 2025 decision to separate DePuy Synthes within an expected 18-to-24-month timeframe and shift its MedTech portfolio toward higher-growth, higher-margin businesses.
For Apollo Global Management, Inc. (NYSE:APO), the attraction is the opportunity to acquire a large, established medical-device franchise with substantial recurring demand from joint-replacement and surgical procedures. A roughly $20 billion valuation against $9.3 billion of 2025 revenue implies a price-to-sales multiple of about 2.2x, giving Apollo room to pursue operational improvements, portfolio rationalization, and margin expansion if the business is acquired at an attractive valuation.
DePuy Synthes also has meaningful scale and leading positions across major orthopedics categories, while J&J has recently invested in technologies that could strengthen the franchise, including an agreement covering Gemtrack tracking technology for robotic and navigation-assisted joint procedures and the acquisition of Expanding Innovations for expandable spine implants. Apollo is also entering the potential deal from a position of considerable financial scale: it had approximately $1.05 trillion of **** ets under management as of June 30, 2026, with $198 billion in equity strategies and $849 billion in credit strategies. Its second-quarter results included $111 billion of gross capital deployment, demonstrating the capacity to execute large transactions.
For Johnson & Johnson (NYSE:JNJ), a sale could accelerate the portfolio transformation that management has already identified as a strategic priority while potentially delivering a sizeable upfront cash inflow. J&J explicitly said its planned orthopedics separation should increase the company's top-line growth and operating margins by allowing it to concentrate on Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision.
The company has also been restructuring orthopedics, with $307 million of restructuring expense in 2025, following $167 million in 2024 and $319 million in 2023, primarily tied to market and product exits. A sale could therefore remove a business that has required restructuring resources while allowing J&J to redeploy capital toward areas it views as higher growth and higher margin.

#NYSE #johnson

Colgate-Palmolive Company (NYSE:CL) is reportedly exploring the sale of several mass-market personal care brands, including Softsoap, Irish Spring and Speed Stick, in a portfolio reshaping effort that could generate more than $1 billion. The company is working with Goldman Sachs on the potential divestiture. Personal care accounted for roughly 17% of Colgate-Palmolive's 2025 net sales, or about $3.5 billion, while oral care remains the company's largest business.
The move comes as Colgate faces pressure in its North American business. Although the company recently reported a 4.9% increase in net sales, organic sales in North America declined 3%, highlighting competitive pressure in a mature market. The strategy is also consistent with a broader consumer-goods shift toward simplifying portfolios and concentrating capital on higher-growth categories. Unilever, Nestlé, and other major consumer companies have similarly been selling slower-growing or non-core businesses.
The biggest positive is that Colgate-Palmolive Company (NYSE:CL) could become a more focused and potentially higher-quality business. Selling brands that no longer fit its highest-priority growth areas would allow management to concentrate capital, marketing spending, and management attention on oral care, pet nutrition, and other businesses where Colgate has stronger competitive advantages. The company's decision would therefore be less about abandoning personal care altogether and more about improving the quality of the remaining portfolio.
A sale could also unlock meaningful shareholder value. If the divestitures generate more than $1 billion, Colgate would have additional capital that could be used for debt reduction, share repurchases, acquisitions, or investment behind its strongest brands. In a mature consumer-staples company, disciplined capital allocation can have an outsized impact on earnings growth and shareholder returns. There is also evidence that portfolio simplification is becoming increasingly attractive across the consumer-goods industry. The Wall Street Journal has highlighted how companies such as Unilever and Nestlé are shedding businesses that add complexity without providing sufficient growth. The underlying argument is that the benefits of owning a very broad portfolio have diminished as consumer preferences become more fragmented and smaller brands become better at responding to trends.
Most importantly, the divestiture could improve Colgate-Palmolive Company (NYSE:CL)'s strategic focus at a time when North American competition is challenging. Rather than allocating resources to defend slower-growing personal-care brands, management could direct investment toward categories and geographies with better long-term growth prospects. That could ultimately support margins and organic growth even if the immediate revenue base becomes smaller.

#colgate #company #care

Targa Resources Corp. (TRGP), headquartered in Houston, Texas, owns, operates, acquires, and develops a portfolio of complementary domestic infrastructure ****** ets. Valued at $62.2 billion by market cap, the company's ****** ets connect natural gas and NGLs to domestic and international markets with growing demand for cleaner fuels and feedstocks.
Companies worth $10 billion or more are generally described as "large-cap stocks," and TRGP perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the oil & gas midstream industry. TRGP benefits from strategic positioning in key shale plays including Permian, STACK, SCOOP, and Bakken, giving it a competitive edge in midstream. Its diversified service portfolio, including the Grand Prix NGL pipeline and Mont Belvieu fractionation capacity, underpins a strong market presence and stable revenue base.
Goldman Sachs Expects Fed Chair Kevin Warsh to Raise Rates This Week — But Not Because of Oil Prices.
Middle East Supply Constraints Lift Crude Oil Prices
Crude Prices Soar as Global Oil Supplies Continue to Tighten

#prices #market #assets #midstream

Oregon billionaires Phil and Penny Knight committed $1.1 billion to the Providence St. Vincent Medical Center and the Providence Heart Institute to build Oregon's first hospital dedicated to women's health, the medical center announced Tuesday.
Phil Knight, co-founder of Nike, and his wife, have supported the institute for more than a decade, previously giving it more than $200 million, including a $75 million gift earlier this year. Along with creating the new women's hospital, their new donation will help the medical center expand cardiovascular care and clinical research and training programs for the heart institute's medical personnel. It will also make it easier to integrate patient care across the medical center.
"Women's health needs change throughout life, and too often patients are asked to navigate multiple specialties and care settings on their own," Ray Moreno, the medical center's CEO, said in a statement. "The Knights' gift is an opportunity to bring these resources together, expanding access for women across Oregon and creating a strong foundation to bridge care gaps in women's health."
The donation is particularly significant because it comes at a moment when U.S. hospitals are seeing far more pregnant patients who are also managing chronic health conditions like diabetes, hypertension, addiction, and behavioral and mental health issues. It also lands at the same time healthcare organizations are struggling with the impact of government funding cuts.
"Resources are scarce, and healthcare is increasingly looking to philanthropy to fill in the gaps," Dan Oseran, the heart institute's executive medical director, told the Chronicle. "A gift like this reduces that friction a little bit and provides the ability to do things we wouldn't otherwise be able to do."

#center #oregon #knight #providence